Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones

Clinical Infectious Diseases

Volumn 20, Issue 4, 1995, Pages 907-912

  Bow, E J ^a,b   Loewen, R ^a,b   Vaughan, D ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Miles Canada Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; CYTARABINE; METRONIDAZOLE; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; FEMALE; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEUTROPENIA; PILOT PROJECTS; QUINOLONES;

EID: 0028929248     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.4.907     Document Type: Article

References (24)

1. Dekker, AW. Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987; 106:7-11.
2. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for the prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106:1-7.
3. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotri-moxazole for infection prophylaxis in acute leukemia: the trade-off for reduced gram-negative sepsis. Am J Med 1988;88:847-54.
4. Karp JE, Dick JD, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Am J Med 1986;81:237-42.
5. The EORTC International Antimicrobial Therapy Cooperative Group.Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
6. The EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trial Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-8.
7. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119(pt 1):584-93.
8. Hughes WT, Armstrong D, Bodey GD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
9. Bow EJ, Rayner E, Scott BA, Louie TJ. Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration. Antimicrob Agents Chemother 1987;31:551-7.
10. Bow EJ. Louie TJ. Riben PD, McNaughton RD, Harding GKM, Ronald AR. Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. Am J Med 1984;76:223-33.
11. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161:397-401.
12. Kaplan ER, Meier R. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Bow EJ, Louie TJ. Emerging role of quinolones in the prevention of gram-negative bacteremia in neutropenic cancer patients and in the treatment of enteric infections. Clin Invest Med 1989; 12:61-8.
14. Bow EJ, Ronald AR. Antibacterial chemoprophylaxis in neutropenic patients—where do we go from here? [editorial]. Clin Infect Dis 1993;17:333-7.
15. de Marie S, van den Broek PJ, Willemze R, van Furth R. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 1993; 12:897-906.
16. Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylacticoral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994;12:1005-11.
17. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994;120:834-44.
18. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994;18:25-31.
19. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS. Acute myeloid leukemia in Manitoba. The consequences of standard 7 + 3 remission-induction therapy followed by high dose cytarabine as postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer 1994;74:52-60.
20. O’Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med 1989;87: 605-13.
21. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
22. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
23. Perfect JR. Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891-7.
24. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.